Lupin & SteinCares Biosimilar Deal

  Published 1 year ago

Lupin partnered with SteinCares to commercialize its ranibizumab biosimilar throughout Latin America (excluding Mexico & Argentina). SteinCares will manage regulatory & commercial aspects, while Lupin handles manufacturing.

  • SteinCares leads LATAM commercialization.
  • Lupin manufactures ranibizumab.
  • Ranibizumab treats various retinal conditions.

You might like these

Cyient-Zinier Team Up for FSM Boost

RateGain Powers Green Motion Growth

Indian Mutual Funds Foreign Assets Drop

Malaysia Extends Biocon Biologics Insulin Contract

Swiggy, Eternal Rally on Margin Hopes

Reliance Unveils AI-Powered Digital Future

TCS & DNA Cloud Partnership

News that matters the most ⚡